At Citigroup's Biopharma Summit 2026, Protagonist Therapeutics CEO Dinesh Patel discussed the company's progress, noting two drug approvals this year supported by strong Phase III data. He emphasized the long development process typical in biotech, with each drug taking over a decade, but expressed optimism about the recent success, including the approval of MIMRYLO with a broad label. Patel acknowledged the challenges ahead but remains positive about the company's trajectory and achievements in the biotech sector.
J.Jill reported strong Q2 earnings, beating estimates with $1.24 EPS and $154.83M revenue, driven by sales growth and direct sales increase. Following this, BTIG raised its price target to $25, suggesting a 15.74% upside. The company also raised its ...
BMO Capital Markets initiated coverage of Lululemon Athletica with an Underperform rating and a $70 price target, citing weakening demand in key markets and margin pressures. This follows a 4% revenue decline in Q2 and a reduced full-year forecast. M...
Core & Main reported strong Q2 earnings with EPS of $0.94, surpassing the $0.92 analyst estimate and showing an 8% increase year-over-year. Revenue reached $2.15 billion, slightly above the $2.14 billion expected, supported by robust municipal infras...
Korn Ferry reported strong Q1 results with earnings per share of $1.43 and revenue of $756.5 million, both exceeding analyst expectations and marking continued growth. Despite this, the stock fell due to conservative guidance for the next quarter, wh...
Copper Quest Exploration plans a private placement to raise up to C$850,000 by issuing 10.6 million units at C$0.08 each, led by major investor Concept Capital Management. Each unit includes one share and a warrant exercisable at C$0.13, expiring in ...
